Emergent Biosolutions (EBS)HHS awarded $2.8K

$2.8K

committed so far

Signed

Apr 10, 2026

Updated

Jun 4, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 8, 2026Federal contract · $21.5M obligatedDepartment of Defense awarded Emergent BioSolutions Inc.: $21.5M obligated to date
2. Feb 25, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On February 25, 2026, the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed John D. Fowler, Jr. as a Class II director effective March 1, 2026, with his initial term expiring at the Company’s 2026 annual meeting of stockholders.”
3. Feb 26, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
4. Apr 10, 2026 · this disclosureFederal contract · $3K obligatedDepartment of Health and Human Services awarded Emergent BioSolutions Inc.: $2.8K obligated to date

What came next

1. Apr 16, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 2 more items)
2. Apr 28, 2026Federal contract · $11K obligatedDepartment of Health and Human Services awarded Emergent BioSolutions Inc.: $11K obligated to date
3. Apr 30, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
4. Jun 26, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors
5. Aug 5, 2026Company filing · Form 8-K · Results, RestructuringAnnounced job cuts, closures or a restructuring, and changed a top executive or board member (and 2 more items)“In connection with the actions described above, on August 5, 2026 the Company also announced that it will eliminate the role of Chief Medical Officer, Head of Research and Development.”

How to read USAspending.gov award record

The obligated amount is money the government has legally committed to pay and has set aside in its accounts. The ceiling, which USAspending calls the potential value, is the most the contract could be worth if every option is exercised and every possible order is placed. The ceiling is a limit, not a payment, and it is often many times the obligated amount.

Full guide: Contract ceiling vs obligated amount: the difference

What else is on file for Emergent Biosolutions

For Emergent Biosolutions, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EBS page.

How this filing works

• Contract ceiling vs obligated amount

Other disclosures at Emergent Biosolutions

• SEC Form 144Oct 7, 2026
• SEC Form 4Oct 7, 2026
• SEC Form 4Oct 5, 2026
• USAspending.gov award recordApr 28, 2026
• USAspending.gov award recordMar 4, 2026
• SEC Form 4Aug 18, 2025

Everything OQRO holds on this company is on its EBS page.